GMI Prenatal and Newborn Genetic Testing Market | Page 2

Browse key industry insights from the report “Prenatal and Newborn Genetic Testing
Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, France,
Italy, UK, Spain, China, India, Japan, South Korea, Australia, Singapore, Argentina, Brazil,
Mexico, South Africa, U.A.E, Saudi Arabia), Application Development Potential, Price
Trends, Competitive Market Share & Forecast, 2017 – 2024” in detail along with the
table of contents:
https://www.gminsights.com/industry-analysis/prenatal-and-newborn-genetic-
testing-market
Diagnostics techniques accounted for major share in technology segment owing to
wide-ranging applications in detection of the birth defects through genomic testing that
include, array-comparative genetic hybridization (aCGH), fluorescence in-situ
hybridization (FISH), and polymerase chain reaction (PCR). PCR is the most preferred
and widely used technique due to its indispensable applications in medical and
biological research along with capability to diagnose inherited diseases with functional
analysis in genes.
U.S. prenatal and newborn genetic testing market will witness substantial growth owing
to existence of advanced technology that include real time and multiplex PCR
techniques coupled with favorable government policies. Structure for screening
programs including postnatal, prenatal, selective or universal differs within the U.S.
advancement in molecular testing enabled diagnosis of intricate sickling disorders and
thalassemia thereby, fueling business growth over the forecast timeframe.
India and China prenatal and newborn genetic testing market is growing significantly
due to improving healthcare facilities, increasing awareness about genetic disorders,
thereby rising demand for screening techniques. Moreover, developing activities and
government supporting policies coupled with growing economic progress are further
boosting industry growth.
Some of the industry players include, Roche Diagnostic, Elitech Group, Myriad Genetics,
Biocartis, IntegraGen, Perkin Elmer, WaferGen Biosystem, Interpace Diagnostics, Quest
Diagnostic, Bio-Rad, AutoGenomics, Bio-Rad, Abbott, Cepheid, EKF Diagnostics, Natera,
Agilent Technologies, Illumina, Ariosa Diagnostics, Sequenom, and Laboratory
Corporation of America Holdings. The industry players focus on strategic alliances,
mergers, partnership and acquisitions for upsurge in firm growth. For instance, in
September 2016, AutoGenomics and WuXi AppTec Lab testing division formed strategic
partnership for introduction of advanced molecular technology of diagnosis to China.
This will provide the company with regional expansion for its products.
2 | Page